Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
http://link.springer.com/article/10.1007/s40267-018-0536-9/fulltext.html
Reference20 articles.
1. Barnes TA, O’Kane GM, Vincent MD, et al. Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer. Front Oncol. 2017;7:113. https://doi.org/10.3389/fonc.2017.00113 .
2. Choo JR, Tan C-S, Soo RA. Treatment of EGFR T790M-positive non-small cell lung cancer. Targ Oncol. 2018;13:141–56.
3. Tan CS, Kumarakulasinghe NB, Huang YQ, et al. Third generation EGFR TKIs: current data and future directions. Mol Cancer. 2018;17(1):29.
4. Lamb YN, Scott LJ. Osimertinib: a review in T790M-positive advanced non-small cell lung cancer. Targ Oncol. 2017;12(4):555–62.
5. Tagrisso (osimertinib) 40 and 80 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2018.
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy;Medicine in Drug Discovery;2024-09
2. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review;Current Topics in Medicinal Chemistry;2024-01
3. Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer;Current Topics in Medicinal Chemistry;2023-08
4. Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study;Advances in Therapy;2023-05-23
5. Use of pyridazinediones for tuneable and reversible covalent cysteine modification applied to peptides, proteins and hydrogels;Chemical Science;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3